| Identification | Back Directory | [Name]
ERYTHROMYCIN A DIHYDRATE | [CAS]
59319-72-1 | [Synonyms]
ERYTHROMYCIN A, DIHYDRATE VETRANAL | [EINECS(EC#)]
204-040-1 | [Molecular Formula]
C37H67NO13.H2O | [MDL Number]
MFCD00144254 | [MOL File]
59319-72-1.mol | [Molecular Weight]
751.945 |
| Hazard Information | Back Directory | [Uses]
Erythromycin A dihydrate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research[3][4]. | [Biological Activity]
Erythromycin dihyrate is a macrolide antibiotic produced by actinomycetes with broad antibacterial activity. It acts by binding to the bacterial 50S ribosomal subunit and inhibits RNA-dependent protein synthesis by blocking transpeptidation and/or translocation reactions without affecting nucleic acid synthesis . | [in vitro]
Erythromycin dihyrate inhibits growth of P. falciparum with IC 50 and IC 90 values of 58.2 μM and 104.0 μM, respectively . | [in vivo]
Mice of the ddY strain began to receive Erythromycin dihyrate 7 days after inoculation of EAC cells, and CDF mice begins to receive Erythromycin dihyrate immediately after inoculation of P388 cells. Erythromycin dihyrate (gastric intubation; 0.1-50 mg/ kg; 30-120 days) decreases tumor growth from the dose of 5 mg/kg, mice receiving 1-10 mg/kg of Erythromycin dihyrate survives much longer than control mice, Only 10% of mice treated with 5 mg/kg of Erythromycin dihyrate had no evidence of tumor formation on day 60, and the mice are alive even at 120 days after inoculation. However, treatment with 50 mg/kg of Erythromycin dihyrate shortens mean survival time in tumorbearing mice by 4-5 days when it compares to controls. | Animal Model: | Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 ce lls | | Dosage: | 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg | | Administration: | Gastric intubation; 30-120 days | | Result: | Decrease tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortens the MST in tumorbearing mice. | | [IC 50]
Macrolide | [References]
[1] Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. DOI:10.1016/s0025-7125(16)31443-2
[2] Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28. DOI:10.1016/j.actatropica.2006.10.008
[3] Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69. DOI:10.1159/000239325
[4] Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67. DOI:10.1016/j.brainres.2014.09.016 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
| Company Name: |
SIGMA-RBI
|
| Tel: |
800 736 3690 (Orders) |
| Website: |
www.sigma-aldrich.com |
|